Farmacogenética e farmacogenômica: uma abordagem nas mutações genéticas nas isoenzimas CYP2C19 e CYP2D6 na metabolização da fluoxetina

• Autor(a) principal: Souza, Laís Ribeiro de Oliveira de
• Data de Publicação: 2020
• Outros Autores: Moreira, Larisse dos Santos, Reis, Leticia Borges, Bolgheroni, Mariana Palhares, Oliveira, Adriano dos Santos
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/1475
• topic: Farmacogenética; Farmacogenômica; Metabolização; Antidepressivos; Farmacoterapia; CNPQ::CIENCIAS DA SAUDE::FARMACIA

Psychopharmacogenetics, that is, the pharmacogenetics of drugs for psychiatric use aims to observe in depth the therapeutic response and side effects of antidepressants and antipsychotics, specifically, fluoxetine, where we can observe the types of mutations in the genes responsible for the metabolization of these drugs , in addition to enabling the identification of different responses to treatment, minimizing side effects, improving results and even identifying new receptors, thereby enabling the monitoring of plasma drug levels. The main aim of advancing pharmacogenomics is to reduce the risks of pharmacotherapy, due the possibilities of creating individualized pharmacotherapies based on the genetic mapping of each individual. The objective of this work is to gather information about how the genetic influence in the process of fluoxetine metabolization, considering mutations in the isoenzymes CYP2D6 and CYP2C19, responsible for the metabolism of several neuroleptics, tricyclic antidepressants, selective serotonin reuptake inhibitors and Beta blockers, significant to demonstrate the importance of studying the pharmacogenetics and pharmacodynamics of antidepressants.